SPDR S&P BIOTECH (XBI)
$74.88
0.00 (0.00%)
XBI Stock Quote Delayed 30 Minutes
Amgen, Inc. (AMGN) Stock Is a Trade for Ailing Portfolios
Investors fear Amgen (AMGN) is a falling knife after dropping on earnings. Use that fear to sell puts for income in AMGN stock.
Previous Close
$69.80
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
36.10M
Day's Range
$66.66 - $75.96
52-Week Range
$66.66 - $105.46
Dividend & Yield
$0.14 (0.18%)
XBI Stock Predictions, Articles, and SPDR S&P BIOTECH News
Is the SPDR S&P Biotech (ETF) (XBI) Done Running?
Biotech stocks are booming, but resistance looms close. Time to take profits on the SPDR S&P Biotech (ETF) XBI calls, but also consider reloading.
Trade of the Day: SPDR S&P Biotech (ETF) (XBI)
XBI hit a new 52-week high of $76.60 on Tuesday before easing back slightly to about $75. And I'm opting to employ one of my preferred bullish strategies here.
The SPDR S&P Biotech (ETF) (XBI) Is on Breakout Watch
Biotech stocks are quietly climbing higher. Here's how to trade the SPDR S&P Biotech (ETF) (XBI) before its seemingly imminent pop.
Direxion Daily S&P Biotech Bear 3X Shares (LABD): The Quick Guide to LABD
Like other leveraged ETFs, Direxion Daily S&P Biotech Bear 3X Shares (LABD) seduces with big potential gains when biotech stocks drop.
How to Profit From the Bulls’ Return to Biotech Stocks (XBI)
Biotech stocks are making a comeback. Use this bullish XBI play to capitalize on continued strength in the sector.
Is Now the Time to Buy Into These 5 Biotech ETFs?
After a painful 2016, biotech stocks are recovering this year. What lies ahead? Let's look at 5 biotech ETFs to find out
Buy Today’s Trump Dump in Biotech Stocks – XBI IBB
Biotech stocks and ETFs like iShares' IBB and SPDR's XBI were hammered Wednesday on Donald Trump's drug pricing comments. Opportunity knocks.
SPDR S&P Biotech (ETF) (XBI): Get on Board the Biotech Train!
Biotech stocks have gained the wind, but the SPDR S&P Biotech (ETF) (XBI) hasn't yet caught up with the market. That's going to change soon.
Surf the Biotech Channel with the SPDR S&P Biotech (ETF) (XBI)
The biotech stock pop is fading, but opportunity lurks for bulls and bears, and you can use the XBI ETF to make some money on its next move.
Try the SPDR S&P Biotech (ETF) (XBI) if You’re Bullish on the Biotech Pause
Biotech stocks remain under accumulation post-election. Play XBI on the cheap to profit from the expected continued upside.
Buy the SPDR S&P Biotech (ETF) (XBI) TODAY – Here’s Why
Biotech stocks and the SPDR S&P Biotech ETF (XBI) just shook off a major bugaboo in Hillary Clinton. The XBI ETF will soar as a result.
Three Big Stock Charts: Metlife Inc (MET), Apple Inc. (AAPL) and SPDR S&P Biotech ETF (XBI)
Apple (AAPL) and the SPDR S&P Biotech ETF (XBI) are going to see selling pressure while Metlife (MET) is unlikely to see the same decline.
Dump Horizon Pharma PLC (HZNP) Stock Now! Don’t Wait!
Horizon Pharma is fading after ugly guidance, and the HZNP stock chart is terrible. Sell this biotech stock before its November report.
Go Long Biotech Stocks for a Donald Trump Win (LABU)
Recently Trump has been gaining in the polls. A Trump win could cause a rally in the biotech sector. Buy calls into the elections.
SPDR S&P Biotech (ETF) (XBI): The Bears Got Nothin’ on Biotech Stocks
Buyers are dominating in biotech stocks. Embrace the relative strength with this XBI play. High-probability profits await.
Biotech SPDR (XBI): Opportunity Lurks Amid the Biotech Swoon
The biotech stock swoon is a blip on the radar, nothing more. Fade the fear by selling juiced up XBI put options.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
